Neochromosome
- Company typePrivate
- Founded-
- HeadquartersLong Island City, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Neochromosome does
Neochromosome, Inc. is a private biotechnology company and subsidiary of Opentrons Labworks, headquartered in Long Island City, New York. It commercializes genome-scale cell engineering technology originally developed for the Synthetic Yeast Genome Project (Sc2.0), which produced the first fully synthetic eukaryotic cells. The company's commercial focus is an Antibody Toolkit for therapeutic antibody discovery and optimization, centered on two core platforms: neoSwitch™, a switchable yeast strain that toggles between surface display and secretion of VHHs, scFvs, and other proteins via simple media changes, eliminating the subcloning and secondary-host expression steps required for characterization assays; and neoDisplay™, pre-transformed yeast for FACS-based isolation of high-affinity binders. The toolkit is complemented by Controlled Mutagenesis Libraries, Defined Variant Libraries, and the Flex neoSwitch™ Workstation, an Opentrons Flex-based automated station for high-throughput purification and characterization.
Neochromosome serves pharmaceutical and biotechnology companies developing biologics — including monoclonal antibodies, bispecifics, CAR-T/TCR targeting domains, and RNA-delivery components — across oncology, immunology, and infectious disease. Its go-to-market is enterprise field sales with three access models: full-service discovery campaigns executed at Neochromosome's facilities (eight-week turnaround), in-house platform delivery with pre-transformed libraries and technical onboarding, and annual flat-fee licensing for unlimited campaigns. In November 2025, Neochromosome launched pre-transformed antibody libraries in partnership with GlobalBio (whose ALTHEA Libraries contain clinically validated scFv/VHH candidates) and opened early access ahead of a planned Q1 2026 full commercial launch. The company is concurrently transitioning its legacy DNA synthesis business to BUILT Biotechnologies as a preferred manufacturing partner, reflecting a strategic narrowing of focus to antibody discovery.
Revenue mechanics span professional services (campaign fees), licensing/royalties (in-house platform delivery), and recurring subscription (annual unlimited-campaign licenses). Pricing is not publicly disclosed; the company's positioning emphasizes >90% reductions in discovery time and cost versus traditional approaches, with lead candidates reportedly identifiable in as few as four weeks. Scientific credibility is anchored by a Scientific Advisory Board chaired by Robert Langer (MIT), with Vinod Khosla, Joel Bader, and Jef Boeke among advisors — all figures tied to the Sc2.0 heritage. As of the available data, Neochromosome has no disclosed external funding rounds, no named end-customer logos, and no published revenue figures; commercial scale remains to be demonstrated post-Q1 2026 launch.
Neochromosome firmographics
Firmographics- Name
- Neochromosome
- Legal name
- Neochromosome, Inc.
- Website
- https://neochromosome.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Neochromosome industry classification
Industry- Product category
- Antibody Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Neochromosome is headquartered
LocationHeadquarters
- HQ city
- Long Island City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Neochromosome business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
Revenue model
- Full-Service Discovery Campaigns: Neochromosome executes complete antibody discovery campaigns at its own facilities. Turnaround time is approximately eight weeks. Customers provide target antigen and receive validated lead candidates ready for downstream characterization.
- In-House Platform Licensing: Pre-transformed libraries are shipped to customers for internal screening programs. Customers run discovery campaigns in-house using Neochromosome's neoSwitch platform, reducing dependency on external CROs and cutting costs significantly.
- Annual Platform Licensing: Unlimited campaigns under a flat-fee annual model. Provides predictable budgeting and maximum flexibility for organizations running multiple antibody discovery programs. Suitable for large pharma companies with high campaign volumes.
- DNA Synthesis Services: Neochromosome provides synthetic DNA and cell engineering services including highly automated synthesis of complex DNA. This revenue stream is being transitioned to BUILT Biotechnologies as a preferred DNA manufacturing partner as Neochromosome shifts focus to other platforms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Full-Service Discovery Campaign |
| Other | Multi-year contract | In-House Platform |
| Subscription | Annual | Annual Licensing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Neochromosome product offering
Product offeringCore offering
Neochromosome provides genome-scale biological engineering tools and services for antibody discovery and biologics development. Its core offering is the neoSwitch platform, a switchable yeast strain that toggles between surface display and secretion of VHHs and scFvs via simple media changes, enabling binder discovery and protein production in the same host without subcloning. The company delivers this through three access models: full-service discovery campaigns at its facilities, in-house platform delivery with pre-transformed libraries, and annual flat-fee licensing, and is supported by the neoDisplay yeast display platform, controlled mutagenesis libraries, and an Opentrons Flex automated workstation.
Product overview
Neochromosome offers genome-scale biological engineering services centered on an Antibody Toolkit platform for antibody discovery and optimization. The core offerings include neoSwitch™ (a switchable yeast platform that toggles between surface display and secretion modes for binder discovery) and neoDisplay™ (pre-transformed yeast for FACS-based yeast display workflows), supplemented by Controlled Mutagenesis Libraries and Defined Variant Libraries. The Flex neoSwitch™ Workstation provides automated high-throughput purification and characterization capabilities built on Opentrons Flex robotics. The platform was developed from technology originally created for The Synthetic Yeast Genome Project (Sc2.0) and is offered as a subsidiary of Opentrons Labworks.
Differentiator
Problem solved
Functional benefit
Products and services
- neoSwitch™ A switchable yeast strain that enables binder discovery and protein production in the same host under chemical trigger control, eliminating subcloning and secondary host expression for characterization (SPR, ELISA). Comes pre-transformed with high-diversity libraries for plug-and-play yeast display workflows and is offered with an optional Opentrons Flex automation workstation for full-service discovery at Neochromosome facilities.
- neoDisplay™ Pre-transformed yeast for antibody discovery that provides turnkey access to yeast display workflows using fluorescence-activated cell sorting (FACS) for isolation of developable, specific, and high-affinity binders, with comparable display levels to EBY100 and a 70% functional display rate.
- Controlled Mutagenesis Libraries Defined mutational ratio libraries enabling systematic exploration of antibody sequence space for affinity maturation and optimization campaigns for antibody engineering customers.
- Defined Variant Libraries Defined DNA sequence libraries for structured variant exploration and antibody engineering, providing precise control over mutation distribution for variant screening campaigns.
- Flex neoSwitch™ Workstation Automated workstation built for the neoSwitch antibody discovery platform on Opentrons Flex robotics, automating purification of 24 or 96 proteins in approximately 2 hours and 15 minutes, BCA/ELISA characterization, Sanger sequencing, and colony PCR with fully walkaway automated purification using magnetic Ni-NTA.
- Full-Service Antibody Discovery Campaigns End-to-end antibody discovery campaigns executed at Neochromosome's facilities using the neoSwitch platform and Opentrons Flex automation, with an approximately eight-week turnaround and delivery of validated lead candidates ready for downstream characterization for pharmaceutical and biotechnology customers.
- Synthetic DNA and Cell Engineering Services Legacy service line providing highly automated synthesis of complex DNA and cell engineering work for customers developing novel therapeutics, sustainable products, and research tools, now being transitioned to BUILT Biotechnologies as Neochromosome prioritizes its neoSwitch antibody discovery platforms.
Quantifiable outcome
- Over 90% reduction in cost compared to traditional antibody discovery approaches
- +4 more outcomes
Companies that use Neochromosome
Customer profileSegments1 record
Ideal customer profiles1 record
Neochromosome technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature6 records
Neochromosome partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- GlobalBiocoreNeochromosome and GlobalBio launched a turnkey solution integrating GlobalBio's clinically validated ALTHEA Libraries (containing billions of scFv and VHH candidates with multiple leads validated in clinical programs) into the Neochromosome neoSwitch yeast strain. The platform enables rapid in-house biologics discovery via yeast display with seamless transition from discovery to soluble antibody production. Early access opened November 2025, with full commercial launch planned Q1 2026. The partnership offers three access models: Full-Service Discovery, In-House Platform, and Annual Licensing.
- Opentrons LabworkscoreNeochromosome is a subsidiary of Opentrons Labworks. The company leverages Opentrons' robotics and automation for its world-class genome foundry. The Opentrons Flex automated workstation is specifically used for neoSwitch antibody discovery workflows.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Neochromosome competitors and assessment
Company assessmentEmerging players
- Specifica (now part of Astellas): Pre-built antibody discovery libraries and engineering platform recently acquired by Astellas. Comparable pre-transformed library offering and overlap with Neochromosome's neoSwitch value proposition.
- BUILT Biotechnologies: High-fidelity DNA assembly and synthesis platform recently selected as Neochromosome's preferred DNA manufacturing partner. Comparable technology stack (synthetic DNA / cell engineering) and a strategic ally that takes over Neochromosome's exiting DNA synthesis business.
Broad incumbents
- Ginkgo Bioworks: Large cell engineering and synthetic biology platform with broad pharma/biotech services. Comparable at the synthetic biology / genome engineering layer that Neochromosome's Sc2.0-derived platform originates from.
Direct peers
- Adimab: Industry-leading yeast-display antibody discovery platform serving major pharma with full-service and licensing models. Closest direct comparator to Neochromosome's neoSwitch/neoDisplay offering and partnership/subscription GTM motion.
- Twist Bioscience: Public synthetic biology platform offering DNA synthesis, antibody libraries (Twist Biopharma), and variant libraries. Overlaps with Neochromosome's pre-transformed library offerings and DNA manufacturing business that is being transitioned to BUILT.
- Generate Biomedicines: AI-driven generative biology platform developing de novo protein therapeutics. Comparable to Neochromosome's controlled mutagenesis/defined variant libraries and shares the broader protein engineering and therapeutic discovery mandate.
- Isogenica: Specialist in VHH/nanobody and synthetic antibody library platforms using display technologies. Comparable to Neochromosome's neoSwitch offering for VHH discovery and shares the customer base of small-to-mid biotechs developing biologics.
- AbCellera Biologics: Public antibody discovery platform combining AI/ML with single-cell screening for pharma partners. Direct competitor to Neochromosome's yeast-display discovery offering, with a much larger operational scale and established enterprise pharma relationships.
- Distributed Bio (Centessa): Pre-built antibody library and discovery platform, now part of Centessa Pharmaceuticals. Direct competitor offering pre-transformed libraries and discovery services to pharma — overlapping with Neochromosome's neoSwitch pre-transformed library value proposition.
Others
- Opentrons Labworks: Parent company and lab-automation platform whose Opentrons Flex robotics power Neochromosome's Flex neoSwitch Workstation. Comparable as the enabling infrastructure for Neochromosome's automated antibody discovery workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Neochromosome social profiles
Digital presenceNeochromosome financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neochromosome leadership team
Management profileNumber of profiles
Profiles8 records
Neochromosome funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neochromosome M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neochromosome
What does Neochromosome do?
Neochromosome provides genome-scale biological engineering tools and services for antibody discovery and biologics development. Its core offering is the neoSwitch platform, a switchable yeast strain that toggles between surface display and secretion of VHHs and scFvs via simple media changes, enabling binder discovery and protein production in the same host without subcloning. The company delivers this through three access models: full-service discovery campaigns at its facilities, in-house platform delivery with pre-transformed libraries, and annual flat-fee licensing, and is supported by the neoDisplay yeast display platform, controlled mutagenesis libraries, and an Opentrons Flex automated workstation.
Is Neochromosome a public or private company?
Neochromosome is a private company. It is classified as corporate owned and is currently operating.
When was Neochromosome founded?
Neochromosome was founded in -1. It employs 11 to 50 people.
Where is Neochromosome based?
Neochromosome is headquartered in Long Island City, United States, in the North America region.
How does Neochromosome make money?
Four revenue lines are on record. Full-Service Discovery Campaigns are the primary driver. The others are in-House Platform Licensing, annual Platform Licensing and DNA Synthesis Services.
Who are Neochromosome's main competitors?
Emerging players on record are Specifica (now part of Astellas) and BUILT Biotechnologies. Ginkgo Bioworks is listed as a broad incumbent. Direct peers are Adimab, Twist Bioscience, Generate Biomedicines, Isogenica, AbCellera Biologics and Distributed Bio (Centessa). Opentrons Labworks is listed as an others.
Does Neochromosome have an API?
No public API is recorded for Neochromosome.
What industry is Neochromosome in?
Neochromosome's product category is Antibody Discovery Platform. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 8731.